Clinical Trials Browser

Phase 2 × Solid Tumors × tomivosertib × Clear all

NCT03616834 2023-03-22

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Phase 2 Completed

Other solid neoplasm

Solid Tumors